School of Human Health Sciences, University of Florence, Florence, Italy.
Center for Psychology and Health, Tages Charity, Florence, Italy.
Personal Ment Health. 2019 Aug;13(3):155-167. doi: 10.1002/pmh.1447. Epub 2019 Jun 6.
Schizotypal personality disorder represents a broad range of maladaptive behaviour, which has been linked to both personality disorder and schizophrenia spectrum disorders; however, to date, little effort has been devoted to developing psychosocial treatment approaches to address it. In response, we conducted two case studies exploring the effects of two metacognitively oriented forms of psychotherapy: metacognitive interpersonal therapy and metacognitive reflection and insight therapy for patients with schizotypal personality disorder. We chose these two forms of therapy as they have been successfully delivered, respectively, to persons with other personality disorders and schizophrenia spectrum disorders. Both treatments consisted of weekly individual psychotherapy sessions over a period of 6 months. General symptoms were assessed during the first week of treatment, at treatment end and at 1 month following treatment using the Symptom Check List-90-Revised, while schizotypal traits were assessed with the Structured Clinical Interview for DSM-5. Both patients completed all sessions, and there were no reports of any adverse outcomes. Both patients achieved reliable change in symptoms (ranging from 4.98 to 9.81) and a significant reduction in schizotypal features. Results provide preliminary evidence of the feasibility of metacognitively oriented interventions for schizotypal personality disorder. © 2019 John Wiley & Sons, Ltd.
分裂型人格障碍代表了广泛的适应不良行为,这些行为与人格障碍和精神分裂症谱系障碍都有关联;然而,迄今为止,人们几乎没有努力开发针对这种障碍的心理社会治疗方法。有鉴于此,我们进行了两项案例研究,探索了两种元认知导向的心理治疗方法的效果:元认知人际治疗和元认知反思与洞察治疗,用于治疗分裂型人格障碍患者。我们选择这两种治疗方法是因为它们已经成功地应用于其他人格障碍和精神分裂症谱系障碍患者。这两种治疗都包括为期 6 个月的每周一次的个体心理治疗。在治疗的第一周、治疗结束时和治疗结束后 1 个月,使用症状检查表 90 修订版评估一般症状,而使用 DSM-5 结构化临床访谈评估分裂型特质。两名患者均完成了所有治疗,没有任何不良后果的报告。两名患者的症状均有可靠的改善(从 4.98 到 9.81),分裂型特征也显著减少。结果初步证明了元认知导向干预对分裂型人格障碍的可行性。©2019 约翰威立父子公司